^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Hodgkin Lymphoma

Related cancers:
TNFRSF8 positive
Hodgkin Lymphoma
CD30-targeted CAR-T immunotherapy
Sensitive
:
C3
SOHO 2022 - 1 week - (New C3)
No biomarker
Hodgkin Lymphoma
brentuximab vedotin
Sensitive
:
A1
NCCN - 2 weeks - (New A2)
No biomarker
Hodgkin Lymphoma
nivolumab
Sensitive
:
A1
NCCN - 2 weeks - (New A2)
No biomarker
Hodgkin Lymphoma
rituximab / hyaluronidase
Sensitive
:
A2
NCCN - 2 weeks - (New A2)
No biomarker
Hodgkin Lymphoma
vinblastine
Sensitive
:
A2
NCCN - 2 weeks - (New A2)
TNFRSF8 positive
Hodgkin Lymphoma
brentuximab vedotin
Sensitive
:
A1
No biomarker
Hodgkin Lymphoma
pembrolizumab
Sensitive
:
A1
No biomarker
Hodgkin Lymphoma
carmustine
Sensitive
:
A1
No biomarker
Hodgkin Lymphoma
penpulimab
Sensitive
:
A1
No biomarker
Hodgkin Lymphoma
AB122
Sensitive
:
A1
No biomarker
Hodgkin Lymphoma
R-CHOP
Sensitive
:
A2
No biomarker
Hodgkin Lymphoma
rituximab
Sensitive
:
A2
No biomarker
Hodgkin Lymphoma
R-CVP
Sensitive
:
A2
No biomarker
Hodgkin Lymphoma
bortezomib
Sensitive
:
A2
No biomarker
Hodgkin Lymphoma
everolimus
Sensitive
:
A2
No biomarker
Hodgkin Lymphoma
carboplatin + etoposide oral + bendamustine
Sensitive
:
A2
No biomarker
Hodgkin Lymphoma
bendamustine
Sensitive
:
A2
No biomarker
Hodgkin Lymphoma
nivolumab + brentuximab vedotin
Sensitive
:
A2
No biomarker
Hodgkin Lymphoma
lenalidomide
Sensitive
:
A2
No biomarker
Hodgkin Lymphoma
GemOx
Sensitive
:
A2
No biomarker
Hodgkin Lymphoma
ICE
Sensitive
:
A2
No biomarker
Hodgkin Lymphoma
ESHAP
Sensitive
:
A2
No biomarker
Hodgkin Lymphoma
DHAP
Sensitive
:
A2
No biomarker
Hodgkin Lymphoma
R-ESHAP
Sensitive
:
A2
No biomarker
Hodgkin Lymphoma
MINE
Sensitive
:
A2
No biomarker
Hodgkin Lymphoma
BEACOPP
Sensitive
:
A2
No biomarker
Hodgkin Lymphoma
IGEV
Sensitive
:
A2
No biomarker
Hodgkin Lymphoma
GVD
Sensitive
:
A2
No biomarker
Hodgkin Lymphoma
GDP
Sensitive
:
A2
No biomarker
Hodgkin Lymphoma
EPIC
Sensitive
:
A2
No biomarker
Hodgkin Lymphoma
BEAM
Sensitive
:
A2
No biomarker
Hodgkin Lymphoma
Bv-AVE-PC
Sensitive
:
B
TNFRSF8 positive
Hodgkin Lymphoma
AFM13
Sensitive
:
C2
CHD8 mutation
Hodgkin Lymphoma
sintilimab
Resistant
:
C3
CELF2 mutation
Hodgkin Lymphoma
sintilimab
Resistant
:
C3
ABCC2 underexpression
Hodgkin Lymphoma
nivolumab + brentuximab vedotin
Sensitive
:
C3
PD-1 underexpression
Hodgkin Lymphoma
nivolumab + brentuximab vedotin
Sensitive
:
C3